1. Executive Summary (Confidence: High)

Ridgeline Discovery, founded in 2017 in Basel, Switzerland, represents a central pillar of Versant Ventures’ unique "hands-on" approach to company building.^[49] As a "Discovery Engine," Ridgeline is not merely a financial vehicle but a fully operational research site staffed by an international team of industry R&D veterans.^[49] Its primary mission is to source breakthrough science from European academic institutes and develop it into independent, foundational biotech companies.^[49]

With Versant Ventures managing over $5.5 billion in capital, Ridgeline leverages deep investment, research, and operating expertise to de-risk early-stage science through in-house laboratory validation.^[49] The organization has successfully launched multiple independent biotech leaders, including Black Diamond Therapeutics, Bright Peak Therapeutics, and Monte Rosa Therapeutics.^[49] By importing "Big Pharma" discipline into the venture space, Ridgeline has become a primary driver of the Swiss and European longevity and oncology biotech ecosystem.^[49]